China Post Exposure Rabies Vaccination After Dog Bite Incidents Manufacturer, Supplier, Factory

As a leading manufacturer, AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. provides Post Exposure Rabies Vaccination After Dog Bite Incidents featuring 100% 14-day seroconversion, serum-free safety, and a 36-month shelf life, fully compliant with global WHO standards for dependable post-bite immunization.

Product Positioning

Post Exposure Rabies Vaccination is a specialized rabies preventive solution engineered for post-exposure scenarios resulting from dog-related injuries, developed by AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. to address the critical need for safe and effective post-bite immunization. This product strictly adheres to WHO rabies exposure classification standards, targeting Category II (non-bleeding bites/scratches) and Category III (bleeding bites/scratches, mucosal contact) exposures, and can be combined with rabies immunoglobulin (20IU/kg) to deliver comprehensive protection for severe cases.

To accommodate diverse procurement requirements, the product is available in two distinct versions: the conventional Vero cell version with mature technology and high cost-effectiveness, and the upgraded serum-free Vero cell version that eliminates bovine serum-related risks. Both versions are freeze-dried, administered exclusively via intramuscular injection, and contain no preservatives, ensuring stability and safety for global distribution. The conventional version holds National Drug Approval Number S20073014, while the serum-free version has completed Phase III clinical trials with its marketing application accepted by CDE, demonstrating robust regulatory compliance and reliability for international buyers.

Core Advantages

Post Exposure Rabies Vaccination After Dog Bite Incidents distinguishes itself through three core advantages that guarantee superior protection and safety for post-bite patients. These advantages are substantiated by clinical data and real-world application, establishing it as a preferred choice for medical institutions and public health programs.

1. Dual-category flexibility: The conventional version has a cumulative supply exceeding 100 million doses, validating its maturity and cost-effectiveness, while the serum-free version eliminates bovine serum contamination risks, with adverse reactions restricted to mild Grade 1-2 and no Grade 4 or above severe reactions, offering enhanced safety for sensitive populations.

2. High-efficiency immune response: The vaccine achieves a 100% antibody seroconversion rate within 14 days, significantly surpassing the WHO effective protection standard of 0.5 IU/ml. The serum-free version’s antibody GMC in both 5-dose and 4-dose groups markedly exceeds protection thresholds, with immune persistence lasting over 3 months, providing long-term protection for exposed individuals.

3. Strong regulatory compliance: The conventional version complies with national pharmacopoeia standards, and the serum-free version supports both the 5-dose and WHO simplified 4-dose schedules, with sequential vaccination compatibility with other brands, making it suitable for global rabies prevention and control scenarios.

Technical Specifications

The technical specifications of Post Exposure Rabies Vaccination are designed to ensure consistent quality and efficacy across all batches. Below is the detailed comparison of the two versions:

Application Scenarios

Post Exposure Rabies Vaccination is widely applicable across multiple post-bite scenarios, providing targeted protection for different user groups. Its versatility makes it a reliable choice for both emergency and routine rabies prevention.

1. Medical institutions: Community hospitals and emergency centers utilize it for urgent post-exposure vaccination after dog bites, often combining it with rabies immunoglobulin to protect Category III exposure patients, ensuring rapid and effective immune response.

2. Pet-related environments: Pet hospitals and markets deploy it to safeguard dog breeders and pet practitioners from occupational exposure, reducing the risk of rabies transmission in high-contact settings.

3. Public health programs: It is suitable for bulk procurement in rabies high-incidence regions like Asia and Africa, supporting large-scale immunization campaigns to control dog-transmitted rabies outbreaks.

Quality Assurance

AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. ensures the quality of Post Exposure Rabies Vaccination through rigorous production and regulatory compliance. The conventional version holds National Drug Approval Number S20073014, confirming its adherence to national pharmacopoeia standards. The serum-free version has completed Phase III clinical trials, with its marketing application accepted by CDE, demonstrating its safety and efficacy. Both versions undergo strict quality control throughout the production process, with the serum-free version eliminating bovine serum to avoid contamination and allergic reactions, ensuring consistent batch-to-batch quality. The 36-month shelf life and 2-8℃ storage requirement further guarantee product stability during distribution and storage.

Customer Trust

Post Exposure Rabies Vaccination After Dog Bite Incidents has earned the trust of global clients through its proven performance and reliable supply. The conventional version has a cumulative supply exceeding 100 million doses, reflecting its widespread adoption and customer confidence. AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. has participated in international exhibitions to showcase the product’s quality and innovation, building strong partnerships with medical institutions and public health agencies. The serum-free version’s successful Phase III clinical trials and CDE marketing application acceptance further validate its reliability, making it a preferred choice for buyers seeking safe and effective post-bite protection.

FAQ

Below are detailed answers to common questions regarding Post Exposure Rabies Vaccination, providing clear guidance for procurement and clinical use.

Q: What is the difference between the conventional and serum-free versions?

A: The conventional version uses traditional Vero cell culture with bovine serum, while the serum-free version eliminates bovine serum throughout production, avoiding contamination and allergic reaction risks. The serum-free version also supports both 5-dose and 4-dose schedules, with immune persistence over 3 months.

Q: What is the immunization schedule for the vaccine?

A: The conventional version follows a 5-dose schedule (days 0, 3, 7, 14, 28), while the serum-free version supports both the 5-dose and WHO simplified 4-dose schedules. Both are administered via intramuscular injection, 1.0ml per dose.

Q: How long does the vaccine provide protection?

A: The serum-free version provides immune persistence over 3 months, with antibody GMC far exceeding the WHO protection threshold. The conventional version achieves 100% seroconversion within 14 days, ensuring rapid and effective protection.

Q: Can the vaccine be combined with rabies immunoglobulin?

A: Yes, for Category III exposures (bleeding bites/scratches, mucosal contact), the vaccine can be combined with rabies immunoglobulin (20IU/kg) to form a comprehensive protective barrier, enhancing protection for severe cases.

Q: What is the shelf life and storage requirement?

A: Both versions have a 36-month shelf life and must be stored at 2-8℃ away from light, with freezing strictly prohibited to maintain product stability and efficacy.

Q: Is the vaccine suitable for global distribution?

A: Yes, the conventional version complies with national pharmacopoeia standards, and the serum-free version has completed Phase III clinical trials with CDE marketing application acceptance. Both support sequential vaccination with other brands, making them suitable for global rabies prevention and control.

Q: What are the common adverse reactions?

A: The serum-free version has adverse reactions mainly limited to mild Grade 1-2, with no Grade 4 or above severe reactions, demonstrating superior safety compared to conventional versions.